TY - JOUR
T1 - Calcium Acetate Control of Serum Phosphorus in Hemodialysis Patients
AU - Emmett, Michael
AU - Sirmon, Maryella D.
AU - Kirkpatrick, Wanda G.
AU - Nolan, Charles R.
AU - Schmitt, Gunther W.
AU - Cleveland, Mark v.B.
PY - 1991/1/1
Y1 - 1991/1/1
N2 - Calcium acetate has many characteristics of an ideal phosphorus binder. It is a readily soluble salt that avidly binds phosphorus in vitro at pH 5 and above. One-dose/one-meal balance studies show it to be more potent than calcium carbonate or calcium citrate. We studied chronic (3-month) phosphorus binding with calcium acetate in 91 hyperphosphatemic dialysis patients at four different centers. All phosphorus binders were stopped for 2 weeks. Calcium acetate at an initial dose of 8.11 mmol (325 mg Ca2+) per meal was then used as the only phosphorus binder. Dose was adjusted to attempt control of predialysis phosphorus level less than 1.78 mmol/L (5.5 mg/100 mL). Final calcium acetate dose was 14.6 mmol (586 mg) Ca2+ per meal. Sixteen patients developed mild transient hypercalcemia (mean, 2.84 mmol/L [11.4 mg/dL]. Initial phosphorus values in mmol/L (mg/dL) were 2.39 (7.4); at 1 month, 1.91(5.9); and at 3 months, 1.68 (5.2). Initial calcium values in mmol/L (mg/dL) were 2.22 (8.9); at 1 month, 2.37 (9.5); and at 3 months, 2.42 (9.7). Initial aluminum values in μmol/L (μg/L) were 2.99 (80.7); and at 3 months were 2.54 (68.4). Initial C-terminal parathyroid hormone (C-PTH) values in nglmL were 14.6; at 1 month, 11.9; and at 3 months, 13.2. Sixty-nine patients then entered a double-blind study. Phosphorus binders were stopped for 1 week. Calcium acetate (at a dose established in a prior study) or placebo was then administered for 2 weeks. Next, patients were crossed to the opposite regimen for 2 weeks. Initial phosphorus was 2.36 mmol/L (7.3 mg/100 mL) and calcium 2.22 mmol/L (8.9 mg/100 mL). Calcium acetate reduced phosphorus to 1.91 mmol/L (5.9 mg/100 mL) and increased calcium to 2.37 mmol/L (9.5 mg/1 00 mL) (both P < 0.01). Placebo had no effect. Calcium acetate at an average dose of 14.6 mmol (586 mg) Ca2+ per meal controlled serum phosphorus in an unselected group of dialysis patients. Aluminum and C-PTH levels decreased. The drug was well tolerated.
AB - Calcium acetate has many characteristics of an ideal phosphorus binder. It is a readily soluble salt that avidly binds phosphorus in vitro at pH 5 and above. One-dose/one-meal balance studies show it to be more potent than calcium carbonate or calcium citrate. We studied chronic (3-month) phosphorus binding with calcium acetate in 91 hyperphosphatemic dialysis patients at four different centers. All phosphorus binders were stopped for 2 weeks. Calcium acetate at an initial dose of 8.11 mmol (325 mg Ca2+) per meal was then used as the only phosphorus binder. Dose was adjusted to attempt control of predialysis phosphorus level less than 1.78 mmol/L (5.5 mg/100 mL). Final calcium acetate dose was 14.6 mmol (586 mg) Ca2+ per meal. Sixteen patients developed mild transient hypercalcemia (mean, 2.84 mmol/L [11.4 mg/dL]. Initial phosphorus values in mmol/L (mg/dL) were 2.39 (7.4); at 1 month, 1.91(5.9); and at 3 months, 1.68 (5.2). Initial calcium values in mmol/L (mg/dL) were 2.22 (8.9); at 1 month, 2.37 (9.5); and at 3 months, 2.42 (9.7). Initial aluminum values in μmol/L (μg/L) were 2.99 (80.7); and at 3 months were 2.54 (68.4). Initial C-terminal parathyroid hormone (C-PTH) values in nglmL were 14.6; at 1 month, 11.9; and at 3 months, 13.2. Sixty-nine patients then entered a double-blind study. Phosphorus binders were stopped for 1 week. Calcium acetate (at a dose established in a prior study) or placebo was then administered for 2 weeks. Next, patients were crossed to the opposite regimen for 2 weeks. Initial phosphorus was 2.36 mmol/L (7.3 mg/100 mL) and calcium 2.22 mmol/L (8.9 mg/100 mL). Calcium acetate reduced phosphorus to 1.91 mmol/L (5.9 mg/100 mL) and increased calcium to 2.37 mmol/L (9.5 mg/1 00 mL) (both P < 0.01). Placebo had no effect. Calcium acetate at an average dose of 14.6 mmol (586 mg) Ca2+ per meal controlled serum phosphorus in an unselected group of dialysis patients. Aluminum and C-PTH levels decreased. The drug was well tolerated.
KW - Calcium acetate
KW - aluminum
KW - hyperphosphatemia
KW - phosphorous binders
KW - renal osteodystrophy
UR - http://www.scopus.com/inward/record.url?scp=0025855058&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025855058&partnerID=8YFLogxK
U2 - 10.1016/S0272-6386(12)80496-3
DO - 10.1016/S0272-6386(12)80496-3
M3 - Article
C2 - 2024656
AN - SCOPUS:0025855058
VL - 17
SP - 544
EP - 550
JO - American Journal of Kidney Diseases
JF - American Journal of Kidney Diseases
SN - 0272-6386
IS - 5
ER -